Search

Search Constraints

Start Over Filtering by: Journal or Parent Publication Title JOURNAL FOR IMMUNOTHERAPY OF CANCER Remove constraint Journal or Parent Publication Title: JOURNAL FOR IMMUNOTHERAPY OF CANCER

Search Results

  • Phase II study of nivolumab and salvage nivolumab/ipilimumab in treatment-naive patients with advanced non-clear cell renal cell carcinoma (HCRN GU16-260-Cohort B)
  • Phase II clinical and immune correlate study of adjuvant nivolumab plus ipilimumab for high-risk resected melanoma
  • Maximizing the value of phase III trials in immuno-oncology: A checklist from the Society for Immunotherapy of Cancer (SITC)
  • Outcomes with adjuvant anti-PD-1 therapy in patients with sentinel lymph node-positive melanoma without completion lymph node dissection
  • IL-7 expands lymphocyte populations and enhances immune responses to sipuleucel-T in patients with metastatic castration-resistant prostate cancer (mCRPC)
  • Phase II study of durvalumab plus tremelimumab as therapy for patients with previously treated anti-PD-1/PD-L1 resistant stage IV squamous cell lung cancer (Lung-MAP substudy S1400F, NCT03373760)
  • Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of breast cancer
  • Pooled safety analysis of tisagenlecleucel in children and young adults with B cell acute lymphoblastic leukemia
  • Association of race/ethnicity with innate immune tumor microenvironment of children with B-acute lymphoblastic leukemia
  • Statin drugs enhance responses to immune checkpoint blockade in head and neck cancer models